Found: 13
Select item for more details and to access through your institution.
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 14, p. 1866, doi. 10.1177/1352458519888610
- By:
- Publication type:
- Article
Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2013, v. 19, n. 2, p. 130, doi. 10.1177/1352458512458844
- By:
- Publication type:
- Article
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Meta‐analysis of the effects of anti‐migraine therapeutics in the rat trigeminovascular nociception model as a tool for design optimization.
- Published in:
- European Journal of Neuroscience, 2023, v. 58, n. 1, p. 2339, doi. 10.1111/ejn.16030
- By:
- Publication type:
- Article
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
- Published in:
- Journal of Neurology, 2020, v. 267, n. 11, p. 3343, doi. 10.1007/s00415-020-09983-1
- By:
- Publication type:
- Article
Progressive Multifocal Leukoencephalopathy Risk Perception in Patients Considering Natalizumab for Multiple Sclerosis.
- Published in:
- International Journal of MS Care, 2022, v. 24, n. 1, p. 13, doi. 10.7224/1537-2073.2020-068
- By:
- Publication type:
- Article
Natalizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis Report Better "Feel-Good" Outcomes on Key Physical, Emotional, and Cognitive Domains Compared to Other Disease-Modifying Therapies.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 87
- By:
- Publication type:
- Article
(DMT02) Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemtuzumab Course in Pooled CAREMS I and II Patients by Number of Additional Courses Received Through Year 9.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 4
- By:
- Publication type:
- Article
Poster 54: Dosing of AbobotulinumtoxinA (Dysport®) Injections for Adults with Lower Limb Spasticity.
- Published in:
- PM & R: Journal of Injury, Function & Rehabilitation, 2018, v. 10, n. 9S1, p. S25, doi. 10.1016/j.pmrj.2018.08.086
- By:
- Publication type:
- Article
Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2017, v. 10, n. 1, p. 3, doi. 10.1177/1756285616670060
- By:
- Publication type:
- Article
Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2014, v. 7, n. 2, p. 83, doi. 10.1177/1756285613518599
- By:
- Publication type:
- Article
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
- Published in:
- Neurology & Therapy, 2019, v. 8, n. 2, p. 367, doi. 10.1007/s40120-019-00159-2
- By:
- Publication type:
- Article
CD4 cell response to interval therapy with natalizumab.
- Published in:
- Annals of Clinical & Translational Neurology, 2015, v. 2, n. 5, p. 570, doi. 10.1002/acn3.190
- By:
- Publication type:
- Article